Astral Steritech Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Astral Steritech Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $3.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Astral Steritech Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $3.4M Trade | TransData Nexus

Astral Steritech Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $3.4M Total Trade · DGFT Verified

Astral Steritech Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.4M across 2 products in 2 therapeutic categories. Based on 67 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ampicillin ($1.8M), Piperacillin ($1.6M), .

Astral Steritech Private Limited — Export Portfolio & Destination Treemap

Astral Steritech Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Astral Steritech Private Limited? — Company Overview & Market Position

Astral Steritech Private Limited, established in 1991 by Dr. Dushyant R. Patel in Vadodara, Gujarat, India, began as a manufacturer of sterile Amoxicillin Sodium using indigenous technology. Over the years, the company expanded its capabilities to produce a range of sterile antibiotic injectable formulations, including Cephalosporin and Semi-Synthetic Penicillin products. In September 2012, Astral Pharmaceutical Industries was rebranded as Astral SteriTech Private Limited to emphasize its focus on sterile manufacturing.

The company is privately held, with an authorized share capital of ₹110 million and a paid-up capital of ₹92.28 million. As of March 2022, Astral Steritech reported a total revenue of ₹1.5 billion, a 35.7% decrease from the previous year, and a net worth decline of 77.21%. In August 2021, Centrient Pharmaceuticals, a global leader in beta-lactam antibiotics, acquired Astral SteriTech, enhancing its portfolio with high-quality sterile injectable antibiotic formulations.

What Does Astral Steritech Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ampicillin$1.8M

Product Portfolio — Top 2 by Export Value

Astral Steritech Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ampicillin	Antibiotics	$1.8M	36	1.3%	5
2	Piperacillin	Advanced Antibiotics	$1.6M	31	1.8%	4

Astral Steritech Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $3.4M. The top category is Antibiotics (53.7% of portfolio), followed by Advanced Antibiotics (46.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Astral Steritech Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Astral Steritech operates a state-of-the-art manufacturing facility located at 911, GIDC Makarpura, Vadodara, Gujarat, India. The plant specializes in the production of sterile antibiotic injectable formulations, including Cephalosporin and Semi-Synthetic Penicillin products. Equipped with advanced technologies from leading pharmaceutical equipment manufacturers, the facility ensures high-quality standards and efficiency across all production stages.

3Key Leadership

As of March 2022, the board of directors of Astral Steritech Private Limited included Nitish Niharkumar Chakravarty, Rohan Dheman, and Manish Kumar Santosh Buchasia. In June 2025, additional directors Kiran Mohanlal Jain, Uttamkumar Mohanlal Jain, Devangiben Jigneshkumar Shah, and Jigneshkumar Ashvinbhai Shah were appointed. The company's leadership has overseen significant developments, including the acquisition by Centrient Pharmaceuticals in August 2021.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Astral Steritech Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Astral Steritech's acquisition by Centrient Pharmaceuticals in August 2021 has likely facilitated access to regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. Centrient's established presence in these regions, combined with Astral Steritech's manufacturing capabilities, positions the company to meet the stringent regulatory requirements of these markets. However, specific regulatory filings, approvals, and market access statuses for Astral Steritech's products in these regions are not publicly disclosed.

2Emerging Markets

The acquisition by Centrient Pharmaceuticals has potentially enhanced Astral Steritech's ability to penetrate emerging markets in Africa, Latin America, and Southeast Asia. Centrient's global network and expertise in beta-lactam antibiotics may enable Astral Steritech to expand its reach in these regions. While the World Health Organization (WHO) prequalification can facilitate access to these markets, specific details regarding Astral Steritech's prequalification status are not publicly available.

3Geographic Strategy

Astral Steritech Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Prior to its acquisition by Centrient Pharmaceuticals, Astral Steritech's manufacturing facility was US FDA-approved, enabling the production of sterile antibiotic injectable formulations for the US market. Specific details regarding approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The acquisition by Centrient Pharmaceuticals in August 2021 may have further streamlined regulatory processes and approvals.

2WHO & EU GMP

While specific details regarding Astral Steritech's World Health Organization (WHO) prequalification and European Union Good Manufacturing Practice (EU GMP) certifications are not publicly available, the company's acquisition by Centrient Pharmaceuticals in August 2021 suggests adherence to international quality standards. Centrient's established presence in global markets indicates that Astral Steritech's manufacturing practices align with WHO and EU GMP requirements.

3CDSCO & Indian Regulatory

Astral Steritech Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the sterile antibiotic injectable formulations market, Astral Steritech competes with other contract development and manufacturing organizations (CDMOs) specializing in beta-lactam antibiotics. The company's acquisition by Centrient Pharmaceuticals in August 2021 enhances its competitive position by expanding its product portfolio and leveraging Centrient's global network. Specific market share comparisons and head-to-head analyses are not publicly disclosed.

2Key Differentiators

Astral Steritech's key differentiators include its specialized focus on sterile antibiotic injectable formulations, state-of-the-art manufacturing facilities, and adherence to international quality standards. The acquisition by Centrient Pharmaceuticals in August 2021 has further strengthened these capabilities, enabling the company to offer a broader range of products and services to its clients.

3Strategic Position

Under Centrient Pharmaceuticals, Astral Steritech's strategic direction focuses on expanding its global presence in the sterile antibiotic injectable formulations market. The company's emphasis on quality manufacturing and regulatory compliance positions it to meet the growing demand for beta-lactam antibiotics worldwide. Future outlooks suggest continued growth and diversification, leveraging Centrient's resources and market access.

Buyer Due Diligence Brief — Evaluating Astral Steritech Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Astral Steritech has a track record of consistent export volume and reliability, as evidenced by its total export value of $3.4 million USD across 67 shipments from 2022 to 2026. The company's portfolio concentration, with its top five products accounting for 100% of exports, indicates a focused approach to its product offerings. The acquisition by Centrient Pharmaceuticals in August 2021 may have further enhanced the company's export capabilities and consistency.

2Certifications to Verify

Importers should verify the following certifications when considering Astral Steritech as a supplier:

FDA Approval: Confirm the facility's registration and product approvals with the US Food and Drug Administration (FDA).

WHO-GMP Certification: Ensure the manufacturing facility complies with World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Verify adherence to European Union Good Manufacturing Practice standards.

Frequently Asked Questions — Astral Steritech Private Limited

How many pharmaceutical products does Astral Steritech Private Limited export from India?

Astral Steritech Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ampicillin ($1.8M), Piperacillin ($1.6M). Total export value is $3.4M.

What is Astral Steritech Private Limited's total pharmaceutical export value?

Astral Steritech Private Limited's total pharmaceutical export value is $3.4M, based on 67 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Astral Steritech Private Limited cover?

Astral Steritech Private Limited exports across 2 therapeutic categories. The largest are Antibiotics (53.7%, 1 products), Advanced Antibiotics (46.3%, 1 products).

Get Full Astral Steritech Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.